2018 American Transplant Congress
Mortality and Kidney Transplantation Outcomes among Chronic Dialysis Patients Who Are Seropositive for Hepatitis C Virus
1Univ of Pennsylvania, Philadelphia, PA; 2Univ of Alabama, Birmingham, AL; 3DaVita, Minneapolis, MN.
Hepatitis C virus (HCV) infection is common among patients receiving chronic dialysis. However, few studies have examined both survival on dialysis as well as transplantation…2018 American Transplant Congress
Waitlist Outcomes and Access to Liver Transplantation for HIV+ Candidates
1JHU, Baltimore; 2SRTR, Minneapolis; 3UAB, Birmingham.
Liver disease is a leading cause of death for HIV+ individuals, and the number of HIV+ liver transplant recipients is increasing. However, since UNOS does…2018 American Transplant Congress
Effect of Direct-Acting Hepatitis C Treatment Regimens on Calcineurin Inhibitors in Liver and Kidney Transplant Patients
Duke University Hospital, Durham, NC.
Background: It has been suggested that treatment with direct-acting antivirals (DAA) for hepatitis C virus (HCV) may decrease calcineurin inhibitor (CNI) concentrations. The purpose of…2018 American Transplant Congress
Use of Hepatitis-C Treatments after Kidney Transplantation: Impact of the Direct-Acting Antiviral Era
Hepatitis C virus (HCV) infection in kidney transplant (KTx) donors or recipients has correlated with adverse outcomes, partly due to limited treatment options. Development of…2018 American Transplant Congress
HCV Ab+/NAT- Organ Donors, and the Challenges of 'Eclipse Windows': Analysis of the OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee (DTAC)
DTAC, United Network for Organ Sharing, Richmond, VA.
Introduction: In 2017, CDC reported new hepatitis C (HCV) cases had tripled over 5 years, mainly due to intravenous drug use (IVDU). As the proportion…2018 American Transplant Congress
Outcomes of Antiviral Treatment (AVT) in Hepatitis C Virus (HCV) Liver Transplant (LT) Patients off Immunosuppression (IS) in Direct Acting Antivirals (DAA) Era
Background: Clearance of HCV under AVT, including DAAs, has been associated with higher risk of rejection, possibly due to the changing immunological environment within the…2018 American Transplant Congress
Hidden Risk of Liver Transplantation for Nonalcoholic Steatohepatitis: A Propensity Score Matched Study
Aim: There is a recent shift in the number of liver transplants (LT) performed in patients with hepatitis C (HCV) to those with non-alcoholic steatohepatitis…2018 American Transplant Congress
Antiviral Therapy for Donor-Derived Hepatitis C Virus Infection after Solid Organ Transplantation
Background: In the context of organ shortage, the opioid epidemic, and the advent of effective direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV), more…2018 American Transplant Congress
Treatment and Outcomes of Orthotopic Liver Transplant Patients Secondary to Hepatitis C Virus: A Single Center Experience
Background: Treatment of acute cellular rejection (ACR) in patients with orthotopic liver transplantation (OLT) secondary to hepatitis C virus (HCV) remains a major challenge due…2018 American Transplant Congress
Transplanting Kidneys from HCV-Infected Donors into HCV-Negative Recipients: Longer-Term and Extended Results of the THINKER Trial
1University of Pennsylvania, Philadelphia; 2Gift of Life, Philadelphia.
Background: In 2016, 800 kidneys from HCV+ deceased donors were discarded. Short-term (6-month) data from the first 10 subjects in the THINKER-1 trial (NCT02743897; funder:…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 28
- Next Page »